'For
the quarter ending Sept 2023, consolidated Net sales (including other operating income) of Torrent Pharmaceuticals has increased 16.11% to Rs 2660 crore compared to quarter ended Sept 2022.Operating profit margin has jumped from 29.64% to 31.02%, leading to 21.50% rise in operating profit to Rs 825.00 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 15.73% to 15.89%. Purchase of finished goods cost rose from 10.11% to 10.72%. Employee cost increased from 17.71% to 18.46%. Other expenses fell from 25.93% to 24.66%. Other income rose 62.50% to Rs 26 crore. PBIDT rose 22.45% to Rs 851 crore. Provision for interest rose 31.88% to Rs 91 crore. Loan funds rose to Rs 4,487.00 crore as of 30 September 2023 from Rs 4,083.00 crore as of 30 September 2022. Inventories declined from Rs 2,328.00 crore as of 30 September 2022 to Rs 2...
Pleaselogin & subscribe to view the full report.
More Reports
-
(17-Aug-2024)
AIA Engineering
Net down 5% on lower sales
-
(17-Aug-2024)
Voltas
Net jump 159% on good operating show
-
(17-Aug-2024)
ABB India
Net up 50% on good operating show
-
(17-Aug-2024)
NHPC
Sales down 2%, net down 1%
|